US 12,280,110 B2
Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
Thomas Barnett, Chapel Hill, NC (US); and David A. Ross, Cary, NC (US)
Assigned to Grifols Worldwide Operations Limited, Dublin (IE)
Filed by Thomas Barnett, Chapel Hill, NC (US); and David A. Ross, Cary, NC (US)
Filed on Aug. 17, 2022, as Appl. No. 17/889,875.
Application 15/883,486 is a division of application No. 15/147,226, filed on May 5, 2016, granted, now 9,913,903, issued on Mar. 13, 2018.
Application 17/889,875 is a continuation of application No. 16/849,083, filed on Apr. 15, 2020, abandoned.
Application 16/849,083 is a continuation of application No. 16/456,689, filed on Jun. 28, 2019, granted, now 10,660,956, issued on May 26, 2020.
Application 16/456,689 is a continuation of application No. 15/883,486, filed on Jan. 30, 2018, abandoned.
Claims priority of provisional application 62/201,917, filed on Aug. 6, 2015.
Prior Publication US 2023/0077855 A1, Mar. 16, 2023
Int. Cl. A61K 39/40 (2006.01); A01K 67/0275 (2024.01); C07K 16/00 (2006.01); C07K 16/12 (2006.01)
CPC A61K 39/40 (2013.01) [A01K 67/0275 (2013.01); C07K 16/00 (2013.01); C07K 16/1214 (2013.01); C07K 16/1228 (2013.01); C07K 16/1232 (2013.01); C07K 16/1282 (2013.01); C07K 2317/52 (2013.01); C07K 2317/70 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)] 14 Claims
 
1. A composition comprising at least 5 mg/mL isolated IgM and a pharmaceutically acceptable carrier, wherein the composition has at least 95% (w/v) of IgM purity and wherein IgG has been removed, wherein the pharmaceutically acceptable carrier is petroleum, peanut oil, soybean oil, mineral oil, sesame oil, polyethylene glycol, glycerin, propylene glycol, aqueous dextrose, a glycerol solution, or an excipient, wherein the excipient is selected from the group consisting of starch, gelatin, silica gel, sodium stearate, glycerol monostearate, talc, glycerol, propylene glycol, a wetting or emulsify agent, or a combination thereof.